Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.7200
-0.0858-10.65%
Post-market: 0.72000.00000.00%16:18 EDT
Volume:1.25M
Turnover:936.90K
Market Cap:86.12M
PE:-0.37
High:0.8300
Open:0.8200
Low:0.7200
Close:0.8058
Loading ...

Invivyd Shares Fall 25% After FDA Declines to Expand Emergency Use Authorization of Co's Covid-19 Drug

THOMSON REUTERS
·
24 Feb

BUZZ-U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop

Reuters
·
24 Feb

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires Live
·
24 Feb

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Feb

Invivyd Shares Down as Regulators Decline Expanded Use for Covid-19 Treatment

Dow Jones
·
24 Feb

Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA

MT Newswires Live
·
24 Feb

BUZZ-Invivyd falls after US FDA declines to expand emergency use of COVID-19 drug

Reuters
·
24 Feb

Invivyd Shares Down 31.1% Premarket After FDA Declines to Expand Emergency Use Authorization of Co's Covid-19 Drug

THOMSON REUTERS
·
24 Feb

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of Pemgarda™ (Pemivibart) to Include Treatment of Mild-to-Moderate Covid-19 for Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing Pemgarda Eua for Pre-Exposure Prophylaxis of Covid-19 in Certain Immunocompromised Patients

THOMSON REUTERS
·
24 Feb

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

GlobeNewswire
·
24 Feb

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Insider Monkey
·
18 Feb

Invivyd partners with football coach Jim Harbaugh for COVID-19 risk awareness

TIPRANKS
·
05 Feb

Invivyd Announces Partnership With Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of Covid-19: Common, Not a Cold

THOMSON REUTERS
·
05 Feb

Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative

MT Newswires Live
·
04 Feb

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
03 Feb

Invivyd Announces Positive Phase 1/2 Clinical Data for Vyd2311, a Monoclonal Antibody Designed to Be a Superior Alternative to Covid-19 Vaccination for the Broad Population

THOMSON REUTERS
·
03 Feb